Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2014; 20(42): 15564-15579
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies
Jeffrey M Sutton, Daniel E Abbott, Department of Surgery, Division of Surgical Oncology, University of Cincinnati Medical Center, Cincinnati, OH 45219, United States
Author contributions: Sutton JM and Abbott DE performed research, analyzed data, and wrote the manuscript.
Correspondence to: Daniel E Abbott, MD, Division of Surgical Oncology, Department of Surgery, University of Cincinnati Medical Center, 234 Goodman Street, ML 0772, Cincinnati, OH 45219, United States. abbottdl@ucmail.uc.edu
Telephone: +1-513-5848900 Fax: +1-513-5840459
Received: December 9, 2013
Revised: January 21, 2014
Accepted: May 28, 2014
Published online: November 14, 2014
Processing time: 343 Days and 10.5 Hours
Revised: January 21, 2014
Accepted: May 28, 2014
Published online: November 14, 2014
Processing time: 343 Days and 10.5 Hours
Core Tip
Core tip: The sequence of multi-modality therapy for pancreatic cancer continues to be debated, though many pancreatic cancer specialists are increasingly utilizing neoadjuvant chemoradiation prior to surgical resection. This manuscript details the rationale for neoadjuvant therapy, the data that supports its use, and the potential of biomarker use for personalizing care in pancreatic cancer.